- Home
- BIVI vs RLYB Comparison
BIVI vs RLYB Comparison
Compare BIVI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- RLYB
- Stock Information
- Founded
- BIVI 2013
- RLYB 2018
- Country
- BIVI United States
- RLYB United States
- Employees
- BIVI N/A
- RLYB N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- RLYB Health Care
- Exchange
- BIVI Nasdaq
- RLYB Nasdaq
- Market Cap
- BIVI 49.8M
- RLYB 42.7M
- IPO Year
- BIVI N/A
- RLYB 2021
- Fundamental
- Price
- BIVI $1.48
- RLYB $0.75
- Analyst Decision
- BIVI Strong Buy
- RLYB Buy
- Analyst Count
- BIVI 1
- RLYB 5
- Target Price
- BIVI $30.00
- RLYB $9.75
- AVG Volume (30 Days)
- BIVI 596.3K
- RLYB 70.1K
- Earning Date
- BIVI 02-11-2025
- RLYB 03-11-2025
- Dividend Yield
- BIVI N/A
- RLYB N/A
- EPS Growth
- BIVI N/A
- RLYB N/A
- EPS
- BIVI N/A
- RLYB N/A
- Revenue
- BIVI N/A
- RLYB $598,000.00
- Revenue This Year
- BIVI N/A
- RLYB N/A
- Revenue Next Year
- BIVI N/A
- RLYB N/A
- P/E Ratio
- BIVI N/A
- RLYB N/A
- Revenue Growth
- BIVI N/A
- RLYB N/A
- 52 Week Low
- BIVI $1.04
- RLYB $0.73
- 52 Week High
- BIVI $33.10
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- BIVI 32.72
- RLYB 37.62
- Support Level
- BIVI $1.45
- RLYB $0.73
- Resistance Level
- BIVI $1.88
- RLYB $0.84
- Average True Range (ATR)
- BIVI 0.16
- RLYB 0.07
- MACD
- BIVI -0.01
- RLYB -0.00
- Stochastic Oscillator
- BIVI 5.08
- RLYB 12.89
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.